NPPB and hydrops fetalis: Likewise, compared to men on modern treatment, women who received modern HF therapy were older (67.2 vs. 64.3 years) and had a higher proportion of NYHA class III-IV (48% vs. 38%), higher LVEF (44% vs. 53% LVEF < 30%), higher NT-proBNP (median 2607 vs. 1841 pg/ml), and lower eGFR (59% vs. 79% eGFR ≥ 60 ml/min/1.73 m2) (data not shown).